Avecho completes treatment phase for Phase III insomnia trial interim analysis
Avecho Biotechnology Ltd (ASX:AVE, OTC:AVEFF, FRA:OEZ) has completed the treatment phase for the final patient required for the planned interim analysis…
0,008€
33,33%
Echtzeit-Aktienkurs Avecho Biotechnology Ltd.
Bid:
Ask: